Holen Sie sich die Stockscreener-App
0.5061
10.01%
0.0461
Schlusskurs vom Vortag:
$0.46
Offen:
$0.45
24-Stunden-Volumen:
508.69K
Relative Volume:
0.71
Marktkapitalisierung:
$24.73M
Einnahmen:
$1.14M
Nettoeinkommen (Verlust:
$-56.27M
KGV:
-0.4169
EPS:
-1.2139
Netto-Cashflow:
$-51.94M
1W Leistung:
+40.49%
1M Leistung:
+40.61%
6M Leistung:
-23.51%
1J Leistung:
-57.83%
1-Tages-Spanne:
$0.44
$0.5398
1-Wochen-Bereich:
$0.365
$0.5398
52-Wochen-Spanne:
$0.27
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.5089 | 22.03M | 1.14M | -56.27M | -51.94M | -1.2139 |
VRTX
Vertex Pharmaceuticals Inc
|
474.34 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
713.42 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.74 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.54 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
320.88 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-04-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-24 | Eingeleitet | Wedbush | Outperform |
| 2023-06-06 | Fortgesetzt | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
Werewolf Therapeutics Inc (HOWL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Werewolf Therapeutics Inc (HOWL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Werewolf Therapeutics (HOWL) Stock Forum and Discussion - Moomoo
HOWL|Werewolf Therapeutics Inc|Price:0.427|Chg%:+0.067 - TradingKey
Werewolf Therapeutics Inc (HOWL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Werewolf Therapeutics Inc (HOWL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Werewolf Therapeutics, Inc. Revenue Breakdown – NASDAQ:HOWL - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Werewolf Therapeutics Inc (HOWL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HOWL stock gains on latest Wolfpack earnings context - Ad-hoc-news.de
HOWL stock trades on fresh data from Werewolf Therapeutics cancer pipeline - Ad-hoc-news.de
Werewolf Therapeutics (HOWL) Q1 2026 Earnings: Narrower Loss Surprises as Biotech Navigates Early Pipeline MilestonesGross Profit Margin - dars.gov.et
Price to earnings forward of Werewolf Therapeutics, Inc. – NASDAQ:HOWL - TradingView
Frontier tech research, news & data - MLQ.ai
HOWL stock stays in focus as Werewolf Therapeutics pursues immuno-oncology pipeline - ad-hoc-news.de
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock By Investing.com - Investing.com Nigeria
Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock - Investing.com
Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares - Stock Titan
Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech - ad-hoc-news.de
Form 144 Werewolf Therapeutics For: 6 July By Investing.com - Investing.com Nigeria
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
Werewolf Therapeutics, Inc. SEC Filing (Jul 6, 2026) - Stock Titan
RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com - Investing.com South Africa
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock By Investing.com - Investing.com Australia
Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
Form 144 Werewolf Therapeutics For: 29 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock - Investing.com
Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares - Stock Titan
Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL) - TradingView
Form 13D/A WEREWOLF THERAPEUTICS For: 26 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales - Stock Titan
Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors - ad-hoc-news.de
Werewolf Therapeutics Inc (HOWL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Werewolf Therapeutics Inc (HOWL) Institutional Confidence - TradingKey
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock By Investing.com - Investing.com Australia
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock - Investing.com UK
[SCHEDULE 13D/A] Werewolf Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 22 June By Investing.com - Investing.com South Africa
Form 4 Werewolf Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Werewolf Therapeutics Inc-Aktie (HOWL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director |
Jul 06 '26 |
Sale |
0.32 |
35,770 |
11,446 |
107,429 |
0.27%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):